Lakewood-Amedex Clears Hurdle for Nu-3 Diabetic Ulcer Trial

The Sarasota-based company is positioning its proprietary topical gel, Nu-3, as a solution to the growing crisis of drug-resistant wound infections. By destabilizing microbial cell membranes, the Bisphosphocin-class antimicrobial offers a distinct mechanism of action designed to bypass the resistance barriers common in traditional antibiotics. Chief Medical Officer Thomas Balzer noted that the trial will leverage the expertise of Study Chair Dr. David G. Armstrong to assess whether the gel can translate preclinical safety and efficacy trends into tangible improvements for patients. This development aligns with federal mandates from the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, reflecting a broader industry push to curb the prevalence of MRSA and other persistent bacterial strains.